- Home
- FLNT vs KPTI Comparison
FLNT vs KPTI Comparison
Compare FLNT & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNT
- KPTI
- Stock Information
- Founded
- FLNT 2001
- KPTI 2008
- Country
- FLNT United States
- KPTI United States
- Employees
- FLNT N/A
- KPTI N/A
- Industry
- FLNT Advertising
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- FLNT Consumer Discretionary
- KPTI Health Care
- Exchange
- FLNT Nasdaq
- KPTI Nasdaq
- Market Cap
- FLNT 39.2M
- KPTI 44.5M
- IPO Year
- FLNT N/A
- KPTI 2013
- Fundamental
- Price
- FLNT $1.88
- KPTI $4.80
- Analyst Decision
- FLNT Hold
- KPTI Buy
- Analyst Count
- FLNT 1
- KPTI 6
- Target Price
- FLNT $3.00
- KPTI $48.50
- AVG Volume (30 Days)
- FLNT 15.4K
- KPTI 55.2K
- Earning Date
- FLNT 08-18-2025
- KPTI 08-05-2025
- Dividend Yield
- FLNT N/A
- KPTI N/A
- EPS Growth
- FLNT N/A
- KPTI N/A
- EPS
- FLNT N/A
- KPTI N/A
- Revenue
- FLNT $243,850,000.00
- KPTI $142,126,000.00
- Revenue This Year
- FLNT N/A
- KPTI $2.09
- Revenue Next Year
- FLNT $11.62
- KPTI $12.90
- P/E Ratio
- FLNT N/A
- KPTI N/A
- Revenue Growth
- FLNT N/A
- KPTI 1.19
- 52 Week Low
- FLNT $1.50
- KPTI $3.51
- 52 Week High
- FLNT $3.83
- KPTI $16.95
- Technical
- Relative Strength Index (RSI)
- FLNT 46.51
- KPTI 55.54
- Support Level
- FLNT $1.85
- KPTI $4.12
- Resistance Level
- FLNT $2.10
- KPTI $4.85
- Average True Range (ATR)
- FLNT 0.10
- KPTI 0.29
- MACD
- FLNT 0.03
- KPTI 0.07
- Stochastic Oscillator
- FLNT 31.25
- KPTI 93.14
About FLNT Fluent Inc.
Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers company is seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.